Tomivosertib free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 207028

CAS#: 1849590-01-7 (free base)

Description: Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling.


Chemical Structure

img
Tomivosertib free base
CAS# 1849590-01-7 (free base)

Theoretical Analysis

MedKoo Cat#: 207028
Name: Tomivosertib free base
CAS#: 1849590-01-7 (free base)
Chemical Formula: C17H20N6O2
Exact Mass: 340.16
Molecular Weight: 340.380
Elemental Analysis: C, 59.99; H, 5.92; N, 24.69; O, 9.40

Price and Availability

Size Price Availability Quantity
5mg USD 410 2 Weeks
10mg USD 785 2 Weeks
25mg USD 1650 2 Weeks
Bulk inquiry

Related CAS #: 1849590-02-8 (HCl)   1849590-01-7 (free base)    

Synonym: eFT-508; eFT 508; eFT508; tomivosertib;

IUPAC/Chemical Name: 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione

InChi Key: HKTBYUWLRDZAJK-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)

SMILES Code: NC1=NC=NC(NC2=CC(C)=C3N(C4(CCCCC4)NC3=O)C2=O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 340.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Megat S, Ray PR, Moy JK, Lou TF, Barragan-Iglesias P, Li Y, Pradhan G,
Wanghzou A, Ahmad A, Burton MD, North RY, Dougherty PM, Khoutorsky A, Sonenberg
N, Webster KR, Dussor G, Campbell ZT, Price TJ. Nociceptor translational
profiling reveals the Ragulator-Rag GTPase complex as a critical generator of
neuropathic pain. J Neurosci. 2018 Nov 20. pii: 2661-18. doi:
10.1523/JNEUROSCI.2661-18.2018. [Epub ahead of print] PubMed PMID: 30459229.


2: Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B,
Ernst JT, Han Q, Goel VK, Han EZR, Huang V, Hung INJ, Jemison A, Jessen KA,
Molter J, Murphy D, Neal M, Parker GS, Shaghafi M, Sperry S, Staunton J, Stumpf
CR, Thompson PA, Tran C, Webber SE, Wegerski CJ, Zheng H, Webster KR.
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated
Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1
and 2 (MNK1/2) Inhibition. J Med Chem. 2018 Apr 26;61(8):3516-3540. doi:
10.1021/acs.jmedchem.7b01795. Epub 2018 Mar 29. PubMed PMID: 29526098.


3: Dreas A, Mikulski M, Milik M, Fabritius CH, Brzózka K, Rzymski T.
Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and
MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK
Inhibitors. Curr Med Chem. 2017;24(28):3025-3053. doi:
10.2174/0929867324666170203123427. Review. PubMed PMID: 28164761.